Andrew Meador, MD
Ophthalmic Plastic and Reconstructive Surgery · Nashville, TNNPI 1134462450
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $69,885 of the $93,513 with a category attached, or 74.7%. Amgen accounts for 99.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $23,022 and has fallen 61.4% since, to $8,890 in 2025.
Across 149 payments — averaging $627.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$93K
- Genentech USA, Inc.$141
- Johnson & Johnson Vision Care, Inc.$45
- Carl Zeiss Meditec AG$19
- Tarsus Pharmaceuticals, Inc.$19
- Bausch & Lomb, A Division Of Bausch Health US, LLC$18
- plus $28 from 2 others
Across 1 payment — averaging $38,120 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$38K
What the payments were for
- Consulting fees$13,17014%
- Speaking & faculty fees$69,88575%
- Travel & lodging$7,2038%
- Food & beverage$3,2253%
- Education$100%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 135 | $93,243 |
| Genentech USA, Inc. | 8 | $141 |
| Johnson & Johnson Vision Care, Inc. | 1 | $45 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Tarsus Pharmaceuticals, Inc. | 1 | $19 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $18 |
| Genentech, Inc. | 1 | $15 |
| Galderma Laboratories, L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$89,444
How this compares
Too few ophthalmic plastic and reconstructive surgery providers in Tennesseeto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TepezzaTeprotumumab-Trbw | 24 | $1,063,742 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 438 | $4,765 |
| Loteprednol Etabonate | 13 | $1,851 |
| ErythromycinErythromycin Base | 157 | $1,511 |
| Doxycycline Hyclate | 52 | $811 |
| Famciclovir | 36 | $797 |
| Methylprednisolone | 80 | $601 |
| Celecoxib | 44 | $331 |
| Cephalexin | 21 | $96 |
| Tramadol Hcl | 22 | $23 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenTepezza | $93,243 | $1,063,74224 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $18 | $1,85113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few ophthalmic plastic and reconstructive surgery providers in Tennesseeon file to place this against a meaningful peer group, so we don't.
Other ophthalmic plastic and reconstructive surgery in Nashville
- Ralph WesleyNashville$270
- Kimberly KlippensteinNashville$212
- Rex YannisChattanooga$19K
- Andrew AnzeljcKnoxville$13K
- Stanley PaceKnoxville$1K
- Michelle NguyenFranklin$645
- Trey PegramClarksville$583
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.